Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept
resulted in a significantly greater reduction from baseline in pulmonary vascular resistance …

Background Despite advances in the management of pulmonary arterial hypertension
(PAH), the mortality rate remains excessive. Long-term efficacy evaluations are needed to …

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial
hypertension (PAH), but the effect on clinical outcomes was unknown. Objectives: To …

Background—Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no
cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment …

Background Treatments for pulmonary arterial hypertension have been mainly studied in
patients with advanced disease (WHO functional class [FC] III and IV). This study was …

Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions …

Objectives: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary
arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil …

BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and
frequently lethal disease with few treatment options. METHODS: We conducted a placebo …